Matches in Nanopublications for { ?s ?p "[Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated ?-aminobutyric acid, type A (GABAA) receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated ?-aminobutyric acid, type A (GABAA) receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_assertion description "[Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated ?-aminobutyric acid, type A (GABAA) receptors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238351.RAfxw3GWNnFVfM9fhovClKpH1xoAqrs3Q3zBz_3q45euI130_provenance.